TY - JOUR
T1 - Fast and Binary Assay for Predicting Radiosensitivity Based on the Theory of ATM Nucleo-Shuttling
T2 - Development, Validation, and Performance
AU - Pereira, Sandrine
AU - Bodgi, Larry
AU - Duclos, Mirlande
AU - Canet, Aurélien
AU - Ferlazzo, Mélanie L.
AU - Devic, Clément
AU - Granzotto, Adeline
AU - Deneuve, Sophie
AU - Vogin, Guillaume
AU - Foray, Nicolas
N1 - Funding Information:
This work was supported by Neolys Diagnostics, the Commissariat General à l’Investissement (Programmes Investissement d'avenir (INDIRA Project), the Cancéropôle Rhône-Alpes (THEODORA project), and the Centre National d’Etudes Spatiales. L.B. was supported by the American University of Beirut (Medical Center) and the Naef K. Basile Institute, and G.V. is supported by the Institut de Cancérologie de Lorraine.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Purpose To examine the possibility of predicting clinical radiosensitivity by quantifying the nuclear forms of autophosphorylated ATM protein (pATM) via a specific enzyme-linked immunosorbent assay (ELISA). Methods and Materials This study was performed on 30 skin fibroblasts from 9 radioresistant patients and 21 patients with adverse tissue reaction events. Patients were divided into 2 groups: radioresistant (toxicity grade <2) and radiosensitive (toxicity grade ≥2). The quantity of nuclear pATM molecules was assessed by the ELISA method at 10 minutes and 1 hour after 2 Gy and compared with pATM immunofluorescence data. Results The pATM ELISA data were in quantitative agreement with the immunofluorescence data. A receiver operating characteristic analysis was applied first to 2 data sets (a training set [n=14] and a validating [n=16] set) and thereafter to all the data with a 2-fold cross-validation method. The assay showed an area under the curve value higher than 0.8, a sensitivity of 0.8, and a specificity ranging from 0.75 to 1, which strongly documents the predictive power of the pATM ELISA. Conclusion This study showed that the assessment of nuclear pATM quantity after 2 Gy via an ELISA technique can be the basis of a predictive assay with the highest statistical performance among the available predictive approaches.
AB - Purpose To examine the possibility of predicting clinical radiosensitivity by quantifying the nuclear forms of autophosphorylated ATM protein (pATM) via a specific enzyme-linked immunosorbent assay (ELISA). Methods and Materials This study was performed on 30 skin fibroblasts from 9 radioresistant patients and 21 patients with adverse tissue reaction events. Patients were divided into 2 groups: radioresistant (toxicity grade <2) and radiosensitive (toxicity grade ≥2). The quantity of nuclear pATM molecules was assessed by the ELISA method at 10 minutes and 1 hour after 2 Gy and compared with pATM immunofluorescence data. Results The pATM ELISA data were in quantitative agreement with the immunofluorescence data. A receiver operating characteristic analysis was applied first to 2 data sets (a training set [n=14] and a validating [n=16] set) and thereafter to all the data with a 2-fold cross-validation method. The assay showed an area under the curve value higher than 0.8, a sensitivity of 0.8, and a specificity ranging from 0.75 to 1, which strongly documents the predictive power of the pATM ELISA. Conclusion This study showed that the assessment of nuclear pATM quantity after 2 Gy via an ELISA technique can be the basis of a predictive assay with the highest statistical performance among the available predictive approaches.
UR - http://www.scopus.com/inward/record.url?scp=85041299151&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2017.10.029
DO - 10.1016/j.ijrobp.2017.10.029
M3 - Article
C2 - 29353653
AN - SCOPUS:85041299151
SN - 0360-3016
VL - 100
SP - 353
EP - 360
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -